NLS Pharmaceutics Ltd. (NASDAQ:NLSP), a Swiss clinical-stage biopharmaceutical company, has undergone a significant transformation. On October 31, 2025, NLSP executed a reverse stock split at a ratio of 10 for 1. This strategic move is part of a broader plan to merge with Kadimastem Ltd., an Israeli company listed on TASE under the symbol KDST.
The merger between NLS Pharmaceutics and Kadimastem has resulted in the formation of NewcelX Ltd., which will trade on the Nasdaq Capital Market under the ticker symbol "NCEL" starting October 31, 2025. This merger, finalized on October 30, 2025, follows an Agreement of Merger and Plan of Reorganization initially dated November 4, 2024. The merger aims to enhance the company's focus on developing innovative therapies for rare and complex central nervous system disorders.
As part of this transition, the traded warrants of the company will be delisted. The new CUSIP number for the shares post-merger and reverse split will be H5835A109. The reverse stock split and merger are strategic steps to strengthen the company's market position and focus on its core mission.
Currently, NLSP's stock price is $0.762, reflecting an increase of 2.97% or $0.022. The stock has traded between a low of $0.76 and a high of $0.83 today. Over the past year, the stock has reached a high of $47.4 and a low of $0.76. The company's market capitalization stands at approximately $2.4 million, with a trading volume of 30.3 million shares on the NASDAQ exchange.
